CFD Research wins contract to discover COVID-19 drugs from Yellowstone National Park
CFD Research has been awarded a $1.5M Phase II Defense Health Agency (DHA) Small Business Innovative Research (SBIR) contract to develop extremophile-derived antivirals to protect soldiers and civilians from COVID-19. Selection was based on achievements during previous drug discovery projects and a novel strategy for targeting the SARS-CoV-2 virus which causes COVID-19.